SCIENCE IN THE NEWS DAILY
Erbitux OK for Colorectal Cancer Patients with Genetic Marker
from USA Today
A new study shows which colorectal cancer patients may benefit from a drug - and which would be better off without it.
The drug Erbitux doesn't work in patients whose tumor has a certain genetic mutation, according to a study of nearly 600 patients, presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago.
About 36 percent of patients in the study have the mutation, in a gene called KRAS, says co-author Eric Van Cutsem, of University Hospital Gasthuisberg in Belgium. All of the patients in the study had colorectal cancer that had spread to other organs.
Read more ...
Connect With Us:
PODCASTS: Expanding With the Cosmos
Using the Atacama Cosmology Telescope (ATC), a 6.5-meter microwave collector in Chile, cosmologists are piecing together the early history of the known universe. In an exclusive American Scientist interview, Arthur Kosowsky—a member of the ATC team and a professor in the Department of Physics and Astronomy at the University of Pittsburgh—discusses how he is using ATC to reach back in time billions of years to search for gravitational waves that could verify inflation and reveal unprecedented details about how the cosmos was born.
To view all multimedia content, click "Latest Multimedia."
Receive notification when new content is posted from the entire website, or choose from the customized feeds available.